Bacteriocin Production, Compositions and Methods of Use
Methods are described herein for generating beneficial compounds and/or materials such as bacteriocins that include contacting ‘challenger’ microbes with the ‘protagonist’ microorganisms. The challenger microbes do not directly manufacture the beneficial compounds and/or materials and instead stimulate the protagonist microorganisms to produce beneficial compounds and materials. The protagonist and/or challenger microorganisms can be administered to a subject so the beneficial compounds and/or materials can be made in vivo. Compositions and methods of using beneficial compounds and/or materials are also described herein.
1 - 18 . (canceled)
19 . A method of treating a disease or disorder in a subject in need thereof, the method comprising administering to the subject a composition comprising one or more bacteriocin product, wherein the one or more bacteriocin product is manufactured by adding at least one type of antagonist to a liquid culture of manufacturing microorganisms comprising at least one bacteria or a combination of bacteria, and incubating the manufacturing microorganisms and the at least one type of challenger microbe together in a liquid culture medium suitable for growth of all bacterial types involved to manufacture the bacteriocin product, wherein the amount of the bacteriocin product produced by the manufacturing organisms in the presence of the antagonist is at least 5-fold greater than the amount of the bacteriocin product produced by the manufacturing organisms in the absence of the antagonist.
20 . The method of claim 19 , wherein at least one type of antagonist stimulates the manufacturing microorganisms to manufacture more of at least one bacteriocin than when the challenger microbes are not present.
21 . The method of claim 19 , wherein the at least one type of antagonist is Weissella viridescens NRRL B-1951.
22 . The method of claim 19 , wherein the at least one type of challenger microbe is in log phase when added to the liquid culture of manufacturing.
23 . The method of claim 19 , wherein the at least one type of challenger microbe is added to the liquid culture of manufacturing microorganisms in log phase.
24 . The method of claim 23 , wherein the at least one type of challenger microbe is added to the liquid culture of manufacturing microorganisms in log phase.
25 . The method of claim 19 , wherein the liquid culture of manufacturing microorganisms is replenished with a carbon source before adding the at least one type of antagoni st.
26 . The method of claim 25 , wherein the liquid culture of manufacturing microorganisms reaches log phase before adding the at least one type of antagonist.
27 . The method of claim 19 , wherein the subject has cancer or may develop cancer.
28 . The method of claim 19 , wherein the subject has cancer.
29 . The method of claim 19 , wherein the subject has leukemia, oral squamous cell carcinoma, mouth cancer, head cancer, neck cancer, stomach cancer, colon cancer, bladder cancer, cervical cancer, or esophageal cancer.
30 . The method of claim 19 , wherein the subject has or may develop GERD.
31 . The method of claim 19 , wherein the disease is cancer.
32 . The method of claim 31 , wherein the cancer is leukemia, oral squamous cell carcinoma, mouth cancer, head cancer, neck cancer, stomach cancer, colon cancer, bladder cancer, cervical cancer, or esophageal cancer.
33 . The method of claim 19 , wherein the disease is GERD.
34 . The method of claim 19 , wherein the disease is an inflammatory disease.
35 . The method of claim 34 , wherein the inflammatory disease is an inflammatory disease of the gastrointestinal track.
36 . The method of claim 19 , wherein the administration is local, oral, intra-intestinal, intra-bladder, intravaginal, dermal, parenteral, intraperitoneal, intravenous, and intraarterial administration.